HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ginseng “country of harvest” labeling

This article was originally published in The Tan Sheet

Executive Summary

Ginseng marketers are required to disclose the country where the herbal ingredient was harvested or face a fine under a bill introduced by Sen. Russ Feingold (D-Wisc.) May 20. The "Ginseng Harvest Labeling Act of 2004" (S 2452) is intended to protect Wisconsin farmers, who produce 97% of the country's ginseng, from smugglers who attempt to label their foreign products as "Wisconsin grown," Feingold notes in floor comments. The Senator says his incorporation of suggestions from the Ginseng Board of Wisconsin into the bill make it stronger than legislation he previously introduced on the issue (1"The Tan Sheet" Oct. 23, 2000, In Brief)...

You may also be interested in...



Ginseng labeling

"Country of origin" statement on all products containing the herbal would be required under bill recently introduced by Sen. Feingold (D-Wisc.). Noting the Badger State produces 97% of the ginseng grown in the U.S., Feingold says in his floor comments that smugglers have been switching higher-quality, "lower pesticide and chemical content" product from Wisconsin with cheaper imports. "Chinese ginseng has a retail value of about $5-$6 per pound, while Wisconsin ginseng is valued at roughly $16-$20 per pound," he notes. The bill, S 3005, referred to the Commerce Committee and likely to be taken up next session, stipulates retailers must indicate where their ginseng is grown or face a fine

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS128626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel